

FOR IMMEDIATE RELEASE

VisionGateAI Awarded Prestigious Andy Hill CARE Fund Grant to Advance Early-Stage Lung Cancer Detection

SEATTLE, WA — September 2026 — VisionGateAI reports that it has received a major grant from the Andy Hill Cancer Research Endowment (CARE) Fund to accelerate the clinical development of its patented Cell-CT™ technology and the LuCED® test. This funding specifically targets the expansion of early-stage lung cancer detection in underserved rural communities where healthcare disparities severely impact survival rates.

The grant supports the advanced development of the LuCED test, a home-collected sputum screening test designed to dramatically improve early-stage cancer detection accuracy and cost-effectiveness. Published clinical study data demonstrates that the technology achieves a 94% sensitivity in detecting stage 1 lung cancer that is typically asymptomatic and highly curable by surgery. This unprecedented performance represents a potential paradigm shift in patient management, transforming how high-risk and rural populations are screened.

"We are deeply grateful for the critical and timely support from the Andy Hill CARE Fund," said VisionGateAI's Founder and CEO, Dr. Alan Nelson. "This non-dilutive grant validates our technology's potential to reduce lung cancer mortality on a systemic level and requires a 1:1 match from out-of-state funding sources to further fuel our clinical roadmap."

This funding positions VisionGateAI to scale its non-invasive screening capabilities, enabling early detection directly to patients at home and closing the care gap for geographically isolated populations. Please see the award announcement and further information that is available from these website links:

<https://www.wacarefund.org/grant-awards/optimization-of-the-non-invasive-luced-test-for-detecting-early-stage-lung-cancer/>

About VisionGateAI

VisionGateAI is a leader in cancer diagnostic AI using its patented medical technology platform focused on saving lives from lung cancer through groundbreaking innovations. Its proprietary Cell-CT™ imaging platform and LuCED® test provide unprecedented clarity for early-stage lung cancer detection when the disease is most treatable.

About the Andy Hill CARE Fund excerpted from its website:

<https://www.wacarefund.org/about/who-we-are/>

CARE Fund's Mission

Andy Hill Cancer Research Endowment (CARE) Fund, Washington's cancer research endowment, invests in public and private entities to promote cancer research in Washington. Through research grants and strategic co-funding partnerships, CARE Fund aims to improve health outcomes by advancing transformational research in the prevention and treatment of cancer.

Leverage Washington's Talent

Increase the value of our public investments by leveraging our state's existing cancer research facilities and talent, as well as clinical and therapeutic resources.

Support the Best Science

Optimize the use of public funds by giving priority to research utilizing the best science and technology with the greatest potential to improve health outcomes.

Advance Innovation

Advance the biotech, medical device, and health care information technology industries in Washington.

Maximize Investment Impact

Incentivize additional investment by requiring private or other nonstate resources to match public funds.